ETrade Capital Management’s Myriad Genetics MYGN Stock Holding History

ETrade Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$396K	Buy	30,350 +1,112	+4%	+$14.1K	0.01%	633
2020 Q2	$332K	Buy	29,238 +10,840	+59%	+$154K	0.01%	634
2020 Q1	$264K	Buy	+18,398	New	+$389K	0.01%	627
2014 Q2	–	Sell	-1,683	Closed	-$58K	–	602
2014 Q1	$58K	Sell	1,683 -2,770	-62%	-$85.8K	﹤0.01%	547
2013 Q4	$94K	Buy	4,453 +1,181	+36%	+$29.9K	0.01%	386
2013 Q3	$77K	Sell	3,272 -277	-8%	-$7.87K	0.01%	371
2013 Q2	$95K	Buy	+3,549	New	+$103K	0.01%	322

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ETrade Capital Management's MYGN Position: Q3 2020 in Review

ETrade Capital Management increased its Myriad Genetics (MYGN) stake by 3.8% in Q3 2020, buying an estimated $14.1K and bringing the position to 30,350 shares worth $396K. The position accounts for 0.01% of the portfolio, ranked #633.

ETrade Capital Management first reported a position in MYGN in Q2 2013 and has held it in 7 quarters since. 192 funds tracked by Wall St. Rank hold MYGN as of Q3 2020.

ETrade Capital Management held 30,350 shares of Myriad Genetics worth $396K as of Q3 2020.
ETrade Capital Management bought 1,112 Myriad Genetics shares in Q3 2020, an estimated $14.1K.
Myriad Genetics made up 0.01% of ETrade Capital Management's portfolio in Q3 2020, its #633 holding.
ETrade Capital Management first reported a position in Myriad Genetics in Q2 2013 and has held it in 7 quarters since.
192 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.